×
Pharming Group Common Stock Net 2013-2024 | PHGUF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pharming Group common stock net from 2013 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Pharming Group Common Stock Net 2013-2024 | PHGUF
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pharming Group common stock net from 2013 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$170.6B
Vertex Pharmaceuticals (VRTX)
$117.1B
Regeneron Pharmaceuticals (REGN)
$111.8B
Bristol Myers Squibb (BMY)
$109.9B
Gilead Sciences (GILD)
$104.8B
CSL (CSLLY)
$95.8B
GSK (GSK)
$79.5B
Alnylam Pharmaceuticals (ALNY)
$34.6B
Argenex SE (ARGX)
$32.5B
BioNTech SE (BNTX)
$28.5B
Biogen (BIIB)
$26.9B
Moderna (MRNA)
$23.5B
BeiGene (BGNE)
$22.7B
Illumina (ILMN)
$21.7B
Genmab (GMAB)
$15.5B
BioMarin Pharmaceutical (BMRN)
$12.9B
Incyte (INCY)
$12.9B
Vaxcyte (PCVX)
$12.4B
Exact Sciences (EXAS)
$12.3B
Insmed (INSM)
$12.3B
Bio-Techne Corp (TECH)
$11.7B
Sarepta Therapeutics (SRPT)
$11.3B
QIAGEN (QGEN)
$9.9B
Bio-Rad Laboratories (BIO.B)
$9.3B
Legend Biotech (LEGN)
$8.7B
Roivant Sciences (ROIV)
$8.3B
Ascendis Pharma (ASND)
$8.2B
Repligen (RGEN)
$7.8B
Revolution Medicines (RVMD)
$7.7B
Halozyme Therapeutics (HALO)
$7.7B